BORA PHARMACEUTICALS CO LTDBB

BORA PHARMACEUTICALS CO LTD

802TWDD
−17−2.08%
At close at 06:38 GMT
TWD
No trades
See on Supercharts

6472 fundamentals

Key facts

Market capitalization‪84.43 B‬TWD
Founded2007
CEOPao Hsi Sheng
About

Bora Pharmaceuticals Co., Ltd. engages in the manufacturing and sales of generic, brand, and over-the-counter drugs. Its products include central nervous system medication, cardiovascular medicine, antibiotics, antivirals, ophthalmic, antipsychotics, dementia drugs, sleeping agents, lowering blood pressure drugs, and health food. The firm operates through the following segments: Sales, Manufacturing, and Other Segment. The Sales segment comprises of the pharmaceuticals and healthcare products. The Manufacturing segment consists of Contract development & manufacturing organization of pharmaceuticals. The Other Segment refers to the distributing and developing pharmaceuticals. Bora Pharmaceuticals was founded on June 12, 2007 and is headquartered in Taipei, Taiwan.

Ownership
‪‪102.84 M‬‬
Free Float shares
‪‪62.28 M‬‬ (60.56%)
Closely held shares
‪‪40.56 M‬‬ (39.44%)
Free Float shares
‪‪62.28 M‬‬ (60.56%)
Closely held shares
‪‪40.56 M‬‬ (39.44%)
Capital structure
Market cap
‪‪84.43 B‬‬
Debt
‪‪18.98 B‬‬
Minority interest
‪‪2.14 B‬‬
Cash & equivalents
‪‪5.92 B‬‬
Enterprise value
‪‪99.63 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪84.43 B‬‬
Price to earning ratio (P/E)
22.90x
Price to sales ratio (P/S)
6.84x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
22.90x
Price to sales ratio (P/S)
6.84x
Valuation ratios
‪0.00‬
‪1.60‬
‪3.20‬
‪4.80‬
‪6.40‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪7.00‬
‪14.00‬
‪21.00‬
‪28.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10%‬
‪14%‬
‪18%‬
‪22%‬
‪26%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Commercial Sales
Contract Development and Manufacturing Organization of Pharmaceuticals
Other
By country
Period: 2024
United States
Europe
Taiwan
Other

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪1.50 B‬‬
‪‪3.00 B‬‬
‪‪4.50 B‬‬
‪‪6.00 B‬‬
Actual
Estimate
Earnings
Next:May 8, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪5.00‬
‪10.00‬
‪15.00‬
‪20.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
36.16%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
1.47%
Last payment
12.00
Last ex-date
Aug 12, 2024
Dividend history
‪1.00%‬
‪1.25%‬
‪1.50%‬
‪1.75%‬
‪2.00%‬
2020
2021
2022
2023
2024
‪0.00‬
‪4.00‬
‪8.00‬
‪12.00‬
‪16.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−7.00 B‬‬
‪0.00‬
‪‪7.00 B‬‬
‪‪14.00 B‬‬
‪‪21.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪6.00 B‬‬
‪‪12.00 B‬‬
‪‪18.00 B‬‬
‪‪24.00 B‬‬
Assets
Liabilities